Jan/Feb 2014

Specialty pharmacy is at the forefront of providing the team-based care and patient counseling now being sought in the developing accountable care organization model.

Xgeva has received FDA approval for a new indication, the treatment of adults and skeletally mature adolescents with giant cell tumor of bone.

Who will stand up for the rights of patients when specialty pharmacy benefit decisions based on cost savings and profits negatively affect patient care?

For patients who require life-sustaining medications, emergency preparedness is essential. Here is a game plan to guide you and your patients when facing the unexpected.

The use of health information technology empowers pharmacists to provide enhanced care by harnessing a wealth of actionable information.

Transitioning infusion therapy patients from hospital outpatient or medical office settings to home care, when appropriate, can result in significant reductions in medical drug spending.

The year 2013 marked the approval of many new specialty medications, with drug debuts and new indications in areas including oncology, hepatitis C, HIV, multiple sclerosis, and inflammatory disease.

The editor-in-chief of Specialty Pharmacy Times discusses the tactics used by pharmacy benefit managers and manufacturers to contain specialty therapy costs.